Unlocking the Potential of KCNS3: A Voltage-Gated Potassium Channel Protein as a Drug Target and Biomarker

Target Name: KCNS3

NCBI ID: G3790

KCNS3

Other Name(s): voltage-gated potassium channel protein Kv9.3 | Potassium voltage-gated channel delayed-rectifier protein S3 | Voltage-gated potassium channel protein Kv9.3 | voltage-gated potassium channel subunit Kv9.3 | Potassium voltage-gated channel modifier subfamily S member 3, transcript variant 1 | potassium voltage-gated channel delayed-rectifier protein S3 | Voltage-gated potassium channel subunit Kv9.3 | KCNS3 variant 1 | potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 | delayed-rectifier K(+) channel alpha subunit 3 | Kv9.3 | MGC9481 | potassium voltage-gated channel modifier subfamily S member 3 | Shab-related delayed-rectifier K+ channel alpha subunit 3 | Delayed-rectifier K(+) channel alpha subunit 3 | KCNS3_HUMAN | KV9.3 | Potassium voltage-gated channel subfamily S member 3

Unlocking the Potential of KCNS3: A Voltage-Gated Potassium Channel Protein as a Drug Target and Biomarker

Potassium (K+) is a crucial ion involved in numerous physiological processes, including muscle contractions, nerve function, and brain activity. The regulation of K+ channels plays a pivotal role in maintaining the resting membrane potential of cells and maintaining the integrity of various biological systems. The voltage-gated potassium channel protein (KCNS3) is a key protein that contributes to this regulation in cells. As a voltage-gated channel protein, Kv9.3 plays a crucial role in maintaining the stability of the plasma membrane potential and is involved in various physiological processes, including neuronal excitability and neurotransmission. In this article, we will discuss the potential of KCNS3 as a drug target and biomarker.

Discovery and Characterization of KCNS3

KCNS3 is a member of the universal protein family, which includes various voltage-gated ion channels that play a crucial role in maintaining the stability of the plasma membrane potential. The KCNS3 gene was first identified in 2004 and has been extensively characterized since then. The protein encoded by the KCNS3 gene is a voltage-gated potassium channel protein that consists of 126 amino acids. It has a unique feature, which is the presence of a 21-amino acid loop, which is known as the \"anomalous subunit.\" This loop is involved in the regulation of the channel's stability and has been implicated in the channel's function.

Functional Characterization of KCNS3

KCNS3 is a critical protein that contributes to the regulation of K+ channels in various biological systems. It is involved in maintaining the stability of the plasma membrane potential, which is critical for the proper functioning of various cellular processes. The KCNS3 protein plays a crucial role in neurotransmission, as it is involved in the regulation of action potential generation and propagation.

KCNS3 is also involved in muscle contractions and neural signaling. It is a key protein that contributes to the regulation of muscle cell excitability and the transmission of signals from the brain to the rest of the body. In addition, KCNS3 is involved in the regulation of neurotransmitter release and the modulation of neurotransmitter signaling.

Drug Targeting and Biomarker Potential

The potential of KCNS3 as a drug target is significant due to its involvement in various physiological processes. The anomalous subunit of KCNS3 has been shown to play a critical role in the regulation of the channel's stability and has been implicated in the channel's function. Therefore, targeting the anomalous subunit of KCNS3 may be an effective way to modulate the channel's activity and improve neuronal excitability.

In addition to its potential as a drug target, KCNS3 also has potential as a biomarker. The regulation of K+ channels is a critical aspect of various physiological processes, including neuronal excitability and neurotransmission. Therefore, the expression of KCNS3 may be an indicator of the function of these channels. The expression of KCNS3 has been shown to be involved in various physiological processes, including neuronal excitability and neurotransmission. Therefore, the expression of KCNS3 may be a useful biomarker for the diagnosis and monitoring of various neurological and psychiatric disorders.

Conclusion

In conclusion, KCNS3 is a voltage-gated potassium channel protein that plays a crucial role in the regulation of various physiological processes. Its anomalous subunit has been shown to be involved in the regulation of the channel's stability and has been implicated in the channel's function. Therefore, targeting the anomalous subunit of KCNS3 may be an effective way to modulate the channel's activity and improve neuronal excitability. Additionally, the expression of KCNS3 may be an indicator of the function of these channels and can be used as a biomarker for the diagnosis and monitoring of various neurological and psychiatric disorders. Further research is needed to fully understand the potential of KCNS3 as a drug target and biomarker.

Protein Name: Potassium Voltage-gated Channel Modifier Subfamily S Member 3

Functions: Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 (PubMed:10484328). Heterotetrameric channel activity formed with KCNB1 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells (By similarity)

The "KCNS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets